Fecal lactoferrin, a marker of intestinal inflammation in children with inflammatory bowel disease

• Authors: Anna Borkowska , Anna Liberek , Grażyna Łuczak , Agnieszka Jankowska , Katarzyna Plata-Nazar , Maria Korzon , Barbara Kamińska
• Languages of publication: EN

Abstracts

EN

The aim of this study was to analyze the usefulness of fecal lactoferrin in the diagnosis and monitoring of inflammatory bowel disease (IBD) in children. The study included 52 children with IBD (24 with Crohn's disease and 28 with ulcerative colitis) aged between 0.92 and 18 years, and 41 IBD-free controls of similar age. Fecal concentration of lactoferrin was determined with a quantitative immunoenzymatic test. Fecal concentration of lactoferrin in children with IBD was significantly higher than in the controls. The cut-off value of fecal lactoferrin concentration optimally distinguishing between the children with IBD and the controls was identified as 13 μg/g. The sensitivity and specificity of this cut-off value equaled 80.7% and 92.7%, respectively, and its positive and negative prognostic values were 96.8% and 63.3%, respectively. Patients diagnosed with moderate Crohn's disease had significantly higher fecal concentrations of lactoferrin than children with the mild or inactive disease. Similarly, children with moderate ulcerative colitis showed significantly higher fecal concentrations of lactoferrin than individuals with the mild condition. No significant relationship was found between the fecal concentration of lactoferrin and the severity of endoscopic lesions. Patients with IBD and a positive result of fecal occult blood test were characterized by significantly higher concentrations of lactoferrin than the individuals with IBD and a negative result of this test. In conclusion, fecal concentration of lactoferrin seems to be a useful parameter for diagnosis and monitoring of IBD in children.

Keywords

EN

fecal lactoferrin; inflammatory bowel disease; children

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2015
• Volume: 62
• Issue: 3
• Pages: 541-545

Dates

published

2015

received

2015-02-02

revised

2015-06-28

accepted

2015-08-31

(unknown)

2015-09-04

Contributors

author

Anna Borkowska

• Department of Pediatrics, Pediatric Gastroenterology, Hepatology and Nutrition, Medical University of Gdansk, Gdańsk, Poland

author

Anna Liberek

• Faculty of Health Sciences with Subfaculty of Nursing, Medical University of Gdansk, Gdańsk, Poland

author

Grażyna Łuczak

• Department of Pediatrics, Pediatric Gastroenterology, Hepatology and Nutrition, Medical University of Gdansk, Gdańsk, Poland

author

Agnieszka Jankowska

• Department of Pediatrics, Pediatric Gastroenterology, Hepatology and Nutrition, Medical University of Gdansk, Gdańsk, Poland

author

Katarzyna Plata-Nazar

• Department of Pediatrics, Pediatric Gastroenterology, Hepatology and Nutrition, Medical University of Gdansk, Gdańsk, Poland

author

Maria Korzon

• Department of Pediatrics, Pediatric Gastroenterology, Hepatology and Nutrition, Medical University of Gdansk, Gdańsk, Poland

author

Barbara Kamińska

• Department of Pediatrics, Pediatric Gastroenterology, Hepatology and Nutrition, Medical University of Gdansk, Gdańsk, Poland

References

• Baker EN, Baker HM (2005) Molecular structure, binding properties and dynamics of lactoferrin. Cell Mol Life Sci 62: 2531-2539.
• Chung-Faye G, Hayee B, Maestranzi S, Donaldson N, Forgacs I, Sherwood R (2007) Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation. Inflamm Bowel Dis 13: 1374-1378.
• D'Inca R, Dal Pont E, Di Leo V, Ferronato A, Fries W, Vettorato MG, Martines D, Sturniolo GC (2007) Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 22: 429-437.
• Dai J, Liu WZ, Zhao YP, Hu YB, Ge ZZ (2007) Relationship between fecal lactoferrin and inflammatory bowel disease. Scand J Gastroenterol 42: 1440-1444.
• Day AS, Ledder O, Leach ST, Lemberg DA (2012) Crohn's and colitis in children and adolescents. World J Gastroenterol 18: 5862-5869.
• Fine KD, Ogunji F, George J, Niehaus MD, Guerrant RL (1998) Utility of a rapid fecal latex agglutination test detecting the neutrophil protein, lactoferrin, for diagnosing inflammatory causes of chronic diarrhea. Am J Gastroenterol 93: 1300-1305.
• Groves ML (1960) The Isolation of a Red Protein from Milk. J Am Chem Soc 82: 3345-3350.
• Iyer S, Lonnerdal B (1993) Lactoferrin, lactoferrin receptors and iron metabolism. Eur J Clin Nutr 47: 232-241.
• Johanson B (1960) Isolation of an iron-containing red protein from human milk. Acta Chem Scand 14: 510-512.
• Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, Dobos GJ, Roth J, Foell D (2007) Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 56: 1706-1713.
• Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB (2003) Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 98: 1309-1314.
• Karolewska-Bochenek K, Lazowska I, Szamotulska K, Grzybowska K, Ryżko J, Iwańczak F, Czerwionka-Szaflarska M, Kaczmarski M, Ignyś I, Albrecht P, Dziechciarz P (2004) Epidemiology of inflammatory bowel disease among children in Poland; a 2-year prospective study's preliminary findings. J Pediatr Gastroenterol Nutr 39: S308.
• Langholz E, Munkholm P, Krasilnikoff PA, Binder V (1997) Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity, and mortality in a regional cohort. Scand J Gastroenterol 32: 139-147.
• Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ (2008) Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 103: 162-169.
• Levay PF, Viljoen M (1995) Lactoferrin: a general review. Haematologica 80: 252-267.
• Lu L, Hangoc G, Oliff A, Chen LT, Shen RN, Broxmeyer HE (1987) Protective influence of lactoferrin on mice infected with the polycythemia-inducing strain of Friend virus complex. Cancer Res 47: 4184-4188.
• Masson PL, Heremans JF, Dive CH (1966) An iron-binding protein common to many external secretions. Clinica Chimica Acta 14: 735-739.
• Montreuil J, Tonnelat J, Mullet S (1960) Preparation and properties of lactosiderophilin (lactotransferrin) of human milk. Biochim Biophys Acta 45: 413-421.
• Oberhelman RA, Guerrero SE, Mercado D, Fernandez ML, Mera R (1999) Observations on the impact of breast-feeding and of intestinal helminthiasis on a rapid agglutination assay for fecal lactoferrin in Nicaraguan children with diarrhea. Pediatr Infect Dis J 18: 944-946.
• Pfefferkorn MD, Boone JH, Nguyen JT, Juliar BE, Davis MA, Parker KK (2010) Utility of fecal lactoferrin in identifying Crohn disease activity in children. J Pediatr Gastroenterol Nutr 51: 425-428.
• Ravikumara M, Sandhu BK (2006) Epidemiology of inflammatory bowel diseases in childhood. Indian J Pediatr 73: 717-721.
• Sawczenko A, Sandhu BK, Logan RF, Jenkins H, Taylor CJ, Mian S, Lynn R (2001) Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet 357: 1093-1094.
• Schoepfer AM, Trummler M, Seeholzer P, Criblez DH, Seibold F (2007) Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum 50: 1697-1706.
• Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F (2008) Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 14: 32-39.
• Schroder O, Naumann M, Shastri Y, Povse N, Stein J (2007) Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Ther 26: 1035-1042.
• Sidhu R, Wilson P, Wright A, Yau CW, D'Cruz FA, Foye L, Morley S, Lobo AJ, McAlindon ME, Sanders DS (2010) Faecal lactoferrin - a novel test to differentiate between the irritable and inflamed bowel? Aliment Pharmacol Ther 31: 1365-1370.
• Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M (2008) Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 14: 40-46.
• Soerensen M, Soerensen S (1939) The proteins in whey. C R Trav Lab Carlsberg 23: 55-99.
• Sudo I, Igawa M, Tsuchiya K, Miyaoka M, Saito T (1993) A study to determine fecal lactoferrin in patients with ulcerative colitis. Nihon Shokakibyo Gakkai Zasshi 90: 824.
• Sugi K, Saitoh O, Hirata I, Katsu K (1996) Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 91: 927-934.
• Turner D, Leach ST, Mack D, Uusoue K, McLernon R, Hyams J, Leleiko N, Walters TD, Crandall W, Markowitz J, Otley AR, Griffiths AM, Day AS (2010) Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut 59: 1207-1212.
• Valenti P, Antonini G (2005) Lactoferrin: an important host defence against microbial and viral attack. Cell Mol Life Sci 62: 2576-2587.
• van der Zaag-Loonen HJ, Casparie M, Taminiau JA, Escher JC, Pereira RR, Derkx HH (2004) The incidence of pediatric inflammatory bowel disease in the Netherlands: 1999-2001. J Pediatr Gastroenterol Nutr 38: 302-307.
• Vermeire S, Van Assche G, Rutgeerts P (2006) Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 55: 426-431.
• Walker TR, Land ML, Kartashov A, Saslowsky TM, Lyerly DM, Boone JH, Rufo PA (2007) Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44: 414-422.

Identifiers

DOI

10.18388/abp.2015_982